Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TELK -- Telik, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (277)	4/10/2002 9:06:58 PM
From: mopgcw	Respond to of 887

A couple new quotes added: Telik Presents TLK286 Mechanism of Action Data at AACR Meeting SOUTH SAN FRANCISCO, Calif., April 10 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK - news) presented data supporting the apoptotic mechanism of action of TLK286, a novel small molecule drug candidate for the treatment of cancer. The data were presented at the annual meeting of the American Association for Cancer Research (AACR) in San Francisco. TLK286 is currently in Phase 2 clinical testing in colorectal, ovarian, non-small cell lung and breast cancer. TLK286 is activated by glutathione S-transferase (GST) P1-1, an enzyme which is over-expressed in many human cancers. Elevated GST P1-1 levels correlate with resistance to commonly used chemotherapeutic drugs. Upon activation, TLK286 initiates an intracellular process known as apoptosis, or programmed cell death. ``TLK286's apoptotic activity is both dose- and time-dependent,'' said James G. Keck, Ph.D., Vice President, Biology Research. ``Following activation by GST P1-1, TLK286 induces apoptosis via the stress response pathway with the activation of the kinases MEK4 and JNK1, and caspase 3. These characteristics suggest a novel mechanism of induction of apoptosis in cancer cells.'' Telik, Inc. of South San Francisco, California, is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat serious diseases for which there is significant demand for new therapies. The company's most advanced drug development programs include: TLK286, a tumor-activated drug candidate for the treatment of major cancers that are resistant to standard treatments, which is currently in Phase 2 clinical trials in colorectal, ovarian non-small cell lung and breast cancer; TLK199, a candidate for the treatment of myelodysplastic syndrome, a form of pre-leukemia, and for increasing white blood cell levels depleted by chemotherapy; and a family of orally active insulin receptor activators for Type 2 diabetes. Telik's product candidates were discovered using its proprietary technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.